Details

Autor(en) / Beteiligte

• Banna, Giuseppe L.
• Cantale, Ornella
• Muthuramalingam, Sethupathi
• Cave, Judith
• Comins, Charles
• Cortellini, Alessio
• Addeo, Alfredo
• Signori, Alessio
• McKenzie, Hayley
• Escriu, Carles
• Barone, Gloria
• Chan, Samuel
• Hicks, Alexander
• Bainbridge, Hannah
• Pinato, David J.
• Ottensmeier, Christian
• Gomes, Fabio

Titel

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Ist Teil von

• International immunopharmacology, 2022-09, Vol.110, p.108985-108985, Article 108985

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •By retrospective study on 308 patients with aNSCLC treated with chemoimmunotherapy.•PFS was similar to that reported in clinical trials.•Number of metastatic sites, histology and SII were independent prognostic factors.•These factors might contribute to a highly discriminating prognostic model. Efficacy outcomes and prognostic factors of real-world patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line chemoimmunotherapy are still limited. In the retrospective Spinnaker study, data was collected from patients in six United Kingdom and one Swiss oncology centres with first-line pembrolizumab plus platinum-based chemotherapy. Efficacy outcomes and potential prognostic factors were estimated aiming at developing a prognostic model. Three-hundred-eight patients were included, 32% ≥ 70 years, with ≥ 3 metastatic sites in 33%, brain or liver metastases in 10% and 12%, respectively. With a median follow-up of 18.0 months (mo.) (range, 15.9–20.1), median overall survival (OS) and progression-free survival (PFS) were 12.7 mo. (range, 10.2–15.2), and 8.0 mo. (range, 7.1–8.8), respectively. The neutrophils-to-lymphocytes ratio (NLR) and systemic immune-inflammatory index (SII) (i.e., NLR × platelet count) were both significantly higher in ECOG PS 1 (p = 0.0147 and p = 0.0018, respectively), underweight or normal body mass index (p = 0.0456 and p = 0.0062, respectively), ≥3 metastatic sites (p = 0.0069 and p = 0.112), pretreatment steroids (p = 0.0019 and p = 0.0017). By MVA, the number of metastatic sites ≥ 3 (p < 0.001 and p = 0.002), squamous histology (p = 0.033 and p = 0.013) and SII ≥ 1444 (p = 0.031 and p = 0.009, respectively) were associated with both worse OS and PFS and led to a highly discriminating three-class risk prognostic model. Real-world PFS with chemoimmunotherapy in aNSCLC patients is similar to that reported in clinical trials. A high number of metastatic sites, squamous histology and high SII are adverse prognostic factors that might contribute to a clinically useful prognostic model.